Certara, which provides model-informed drug development, regulatory science, real-world evidence (RWE) and market access services, has added the full team from Compass Strategic Consulting to its evidence and access group.
Paul Gallagher, formerly the president of Compass, is now Certara’s vice president of US access strategy.
“Determining cost versus value for novel drug therapies is an economic and ethical issue impacting health care around the world, and it is at the heart of our expanded offering,” said Roman Casciano, SVP of Certara Evidence and Access.
Of “immediate benefit” to its customers, is Compass’ due diligence practice, which “can respond rapidly to deal demands,” said Casciano in a statement addressing the deal.
Certara Chief Corporate Affairs Officer Ellen Leinfuss told us the combined Certara Evidence and Access team will bring its BaseCase value communications software platform to the US market. "This platform facilitates interactive value communications tools, budget and risk models, real-world evidence dashboards, and outcomes-based agreements calculators, to name a few," she said.
Compass Strategic Consulting's team also will work in other parts of Certara, said Leinfuss, specifically, providing pricing guidance in novel development areas such as oncology and rare diseases and for novel treatments, including cell and gene therapies.
Certara earlier this year launched version 18 of its physiologically-based pharmacokinetic (PBPK) Simcyp Simulator with new features including advanced food staggering and tumor models to optimize trial design and dose selection.